positive lung cancer (ROS1)-positive NSCLC According to research, about 50% to 60% of people with EGFR- or ALK-positive lung cancer go on to develop brain mets. Why is this? Doctors aren’t sure.

Other genetic changes that drive tumor growth include mutations in the genes ALK and ROS1, which are found in about 5% of lung cancer cases in non-smokers. These mutations are more often seen in ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo ...

has been cleared for patients with ROS1-positive non-small-cell lung cancer (NSCLC) on the back of overall response rate (ORR) data from the phase 1/2 TRIDENT-1 study after a priority review by ...

The Food and Drug Administration (FDA) has only approved ceritinib (Zykadia) and lorlatinib (Lorbrena) to treat ALK-positive lung cancer. However, a doctor may still prescribe if you have ROS1 ...

Currently there is a lack of treatments for ROS1-positive NSCLC, especially for people whose lung cancer has spread to the brain. Factoring the discount, Rozlytrek costs up to £42,500 per QALY ...

“ROS1-positive NSCLC is a rare form of lung cancer with a unique patient journey to navigate,” said Janet Freeman-Daily, Co-Founder and President of The ROS1ders. “At The ROS1ders, we are ...

In India, lung cancer is becoming increasingly common ... that can be targeted by specific treatments, such as EGFR, ALK, ROS1 on tumour biopsy tissue samples. Tumour biopsy is the gold standard ...

Lung cancer was originally classified according ... Currently, seven genes (EGFR, ALK, ROS1, BRAF, NTRK, MET and RET) have therapies that have been approved by the United States Food and Drug ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market seg ...